JP2008527041A5 - - Google Patents

Download PDF

Info

Publication number
JP2008527041A5
JP2008527041A5 JP2007552198A JP2007552198A JP2008527041A5 JP 2008527041 A5 JP2008527041 A5 JP 2008527041A5 JP 2007552198 A JP2007552198 A JP 2007552198A JP 2007552198 A JP2007552198 A JP 2007552198A JP 2008527041 A5 JP2008527041 A5 JP 2008527041A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
aryl
heterocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007552198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008527041A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/001483 external-priority patent/WO2006078598A2/en
Publication of JP2008527041A publication Critical patent/JP2008527041A/ja
Publication of JP2008527041A5 publication Critical patent/JP2008527041A5/ja
Withdrawn legal-status Critical Current

Links

JP2007552198A 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤 Withdrawn JP2008527041A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64493405P 2005-01-19 2005-01-19
PCT/US2006/001483 WO2006078598A2 (en) 2005-01-19 2006-01-13 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
JP2008527041A JP2008527041A (ja) 2008-07-24
JP2008527041A5 true JP2008527041A5 (https=) 2009-02-26

Family

ID=36692770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552198A Withdrawn JP2008527041A (ja) 2005-01-19 2006-01-13 有糸分裂キネシン阻害剤

Country Status (7)

Country Link
US (1) US20090124641A1 (https=)
EP (1) EP1855685A4 (https=)
JP (1) JP2008527041A (https=)
CN (1) CN101106998A (https=)
AU (1) AU2006206675A1 (https=)
CA (1) CA2593166A1 (https=)
WO (1) WO2006078598A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004313A (es) * 2007-11-07 2010-07-06 Schering Corp Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113549000A (zh) * 2020-04-23 2021-10-26 复旦大学 用于预防或治疗脂质代谢相关疾病的化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183931A (en) * 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2004064741A2 (en) * 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS

Similar Documents

Publication Publication Date Title
JP2008527038A5 (https=)
Lang et al. Nitrogen-containing heterocycles as anticancer agents: An overview
Ruch et al. Hedgehog signaling pathway and cancer therapeutics: progress to date
RU2468021C2 (ru) Гетероциклические соединения и их применение
JP2009514881A5 (https=)
JP2022017295A5 (https=)
Sahebjam et al. The utility of hedgehog signaling pathway inhibition for cancer
JP2007517071A5 (https=)
JP7182304B2 (ja) インドリノン化合物の使用
EP4161511A1 (en) Novel small molecules for targeted degradation of untargetable kras in cancer therapy
JP2018504418A5 (https=)
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
Jin et al. Curaxin CBL0137 exerts anticancer activity via diverse mechanisms
JP2009541223A5 (https=)
RU2008122048A (ru) Аминопиримины в качестве ингибиторов киназ
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
RU2002120515A (ru) Гетероциклические соединения, содержащие сульфонамидные группы
RU2017104909A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2008527041A5 (https=)
Abdelaleem et al. Prospects for repurposing CNS drugs for cancer treatment.
Dai et al. Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents
JP2008527039A5 (https=)
JP2020523354A5 (https=)
NZ598758A (en) N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
MX2007004549A (es) Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico.